() Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 21, 2013
(Stock Blog Hub,
5/15/13)
Aegerion Pharmaceuticals, Inc. (AEGR) reported first quarter 2013 net loss per share of 64 cents, narrower than the Zacks Consensus Estimate of a loss of 72 cents, but...(read more)
(Stock Blog Hub,
1/16/13)
Aegerion Pharmaceuticals, Inc. (AEGR) recently provided more details on its public offering. The offering is expected to close on Jan 16, 2013.
The total offer consists of...(read more)
(Penny Stock DD,
3/17/11)
Aegerion Pharmaceuticals has received federal orphan drug status for its lead candidate, a treatment for people with severe lipid disorders.
Orphan drug status is given to drugs that...(read more)
Aegerion Pharmaceuticals (AEGR) Company Overview
There is no analysis for yet. But you can go to Wikinvest to help create one!
